- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Celltrion's autoimmune disease treatment available in 5 European countries | 2 | Korea Joongang Daily | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| Do | Celltrion's autoimmune disease treatment hits 5 major European countries | 1 | Korea Herald | ||
| 16.01. | Celltrion Showcases Innovation and Growth Plans at JPMHC 2025 | 2 | BusinessKorea | ||
| 16.01. | Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut: chairman | - | Korea Economic Daily | ||
| 15.01. | Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue | 1 | Korea Joongang Daily | ||
| 15.01. | Celltrion envisions 13 new drugs; Samsung Bio unveils 6th plant plan | 2 | Korea Times | ||
| 08.01. | Celltrion to reveal four-year road map at J.P. Morgan Healthcare Conference | 4 | Korea Joongang Daily | ||
| 08.01. | Celltrion to unveil novel drug roadmap at JP Morgan Healthcare Conference | 1 | Korea Herald | ||
| 08.01. | Celltrion to Unveil New Drug Development Strategy at JPMHC 2025 | 1 | BusinessKorea | ||
| 06.01. | Samsung, Celltrion to exhibit at J.P. Morgan Healthcare Conference | 1 | Korea Joongang Daily | ||
| 27.12.24 | Dividendenbekanntmachungen (27.12.2024) | 14.532 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 3 JPY 0,0182 EUR AGC INC JP3112000009 105 JPY 0,6373 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0... ► Artikel lesen | |
| 18.12.24 | FDA approves Celltrion's biosimilar of J&J's Stelara | 15 | Seeking Alpha | ||
| 18.12.24 | Celltrion's Crohn's treatment set for February U.S. release | 1 | Korea Joongang Daily | ||
| 18.12.24 | Celltrion gets approval of Steqeyma from FDA | 1 | Korea Economic Daily | ||
| 18.12.24 | Celltrion Group Launches Celltrion BioSolutions to Enter CDMO Market | 2 | BusinessKorea | ||
| 17.12.24 | Celltrion BioSolutions launched to venture into CDMO | 1 | Korea Economic Daily | ||
| 17.12.24 | Celltrion launches CDMO subsidiary BioSolutions to achieve 3 trillion won sales goal | 2 | Korea Joongang Daily | ||
| 17.12.24 | Celltrion launches CDMO subsidiary to drive growth beyond biosimilars | 1 | Korea Herald | ||
| 17.12.24 | Celltrion establishes new subsidiary for CDMO business | 2 | Yonhap News | ||
| 16.12.24 | Celltrion's 4 new biosimilars win EU approval recommendation | 1 | Korea Economic Daily |
Seite:
1 2 3 4 5 Weiter >>
133 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 54,81 | 0,00 % | Der neue KI-Star: Cathie Wood und Nancy Pelosi haben schon zugegriffen - Tempus AI wird zum Muss! | © Foto: Gorodenkoff / Stock.adobe.comAufgepasst Siri und Alexa! Olivia, die KI-gestützte Gesundheits-Concierge-App von Tempus AI, ist auf dem Weg. Allein ihre Ankündigung bescherte Tempus AI den besten... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS | 13,160 | 0,00 % | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 | ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | Peering Into ADMA Biologics' Recent Short Interest | ||
| AVIDITY BIOSCIENCES | 30,130 | 0,00 % | Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) | ||
| QIAGEN | 43,470 | -2,45 % | DAX: Fällt der nächste Rekord? Außerdem: Aktien von Qiagen und UnitedHealth im Fokus | Der DAX hat am Freitag den dritten Rekordtag in Folge verbucht. Kurz vor dem Amtsantritt von Donald Trump als US-Präsident stieg der Leitindex im frühen Handel erstmals über die Marke von 20.700 Punkten.... ► Artikel lesen | |
| IMMUNOVANT | 23,400 | 0,00 % | Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential | ||
| DYNE THERAPEUTICS | 13,690 | 0,00 % | Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 49,120 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen | |
| DISC MEDICINE | 57,06 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| EVOTEC | 8,075 | +2,09 % | Bechtle, CompuGroup, Continental, Evotec, SMA Solar, Varta u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,520 | 0,00 % | Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Should You Sell? | ||
| ONCO-INNOVATIONS | 1,650 | +14,11 % | EQS-Media: Übernahme voraus: Onco-Innovations Ltd. unterzeichnet Letter of Intent mit Inka Health Corp. | EQS-Media / 23.01.2025 / 12:12 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) Onco oder das Unternehmen, freut sich bekannt zu geben, dass es mit Inka Health Corp., die eine... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 5,610 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| JANUX THERAPEUTICS | 44,620 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| VERVE THERAPEUTICS | 7,990 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.
